Does hybridoma technology still have a place in transfusion medicine?

被引:0
作者
Yuan, FF [1 ]
Watt, JM [1 ]
Geczy, AF [1 ]
机构
[1] ARCBS Endeavour, Dept Tissue Typing, Sydney, NSW 2000, Australia
关键词
D O I
10.1053/tmrv.2002.33436
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hybridoma technology has contributed to virtually all areas of biology and medicine and set the scene for important advances in cell biology and immunodiagnostics. Blood transfusion and transfusion medicine have benefited significantly from development in hybridoma technology, and this has resulted in the generation of a wide range of monoclonal antibodies to human blood group antigens. These antibodies have also had an impact on diagnostic techniques such as enzyme-linked immunosorbent assay and flow cytometry as well as on the application of therapeutic agents in the clinical environment. However, rapid advances in the development of knockout and transgenic mice as well as in nucleic acid-based immunization may well lead hybridoma technology into a new era. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:230 / 238
页数:9
相关论文
共 68 条
[1]   CHARACTERIZATION OF A MURINE MONOCLONAL-ANTIBODY SPECIFIC FOR THE HUMAN P1 BLOOD-GROUP ANTIGEN [J].
BAILLY, P ;
CHEVALEYRE, J ;
SONDAG, D ;
FRANCOISGERARD, C ;
PIQUET, Y ;
VEZON, G ;
CARTRON, JP .
MOLECULAR IMMUNOLOGY, 1987, 24 (02) :171-176
[2]   INVITRO EVALUATION OF THE ROLE OF THE DUFFY BLOOD-GROUP IN ERYTHROCYTE INVASION BY PLASMODIUM-VIVAX [J].
BARNWELL, JW ;
NICHOLS, ME ;
RUBINSTEIN, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (05) :1795-1802
[3]   Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens [J].
Berry, JE ;
Murphy, CM ;
Smith, GA ;
Ranasinghe, E ;
Finberg, R ;
Walton, J ;
Brown, J ;
Navarrete, C ;
Metcalfe, P ;
Ouwehand, WH .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (03) :735-742
[4]   CHARACTERIZATION OF THE D-ANTIGENS, C-ANTIGENS, E-ANTIGENS AND G-ANTIGENS OF THE RH BLOOD-GROUP SYSTEM WITH HUMAN MONOCLONAL-ANTIBODIES [J].
BLOY, C ;
BLANCHARD, D ;
LAMBIN, P ;
GOOSSENS, D ;
ROUGER, P ;
SALMON, C ;
MASOUREDIS, SP ;
CARTRON, JP .
MOLECULAR IMMUNOLOGY, 1988, 25 (09) :925-930
[5]   HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].
CARTER, P ;
PRESTA, L ;
GORMAN, CM ;
RIDGWAY, JBB ;
HENNER, D ;
WONG, WLT ;
ROWLAND, AM ;
KOTTS, C ;
CARVER, ME ;
SHEPARD, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289
[6]  
Cerutti A, 1998, J IMMUNOL, V160, P2145
[7]   The molecular biology of prion propagation [J].
Clarke, AR ;
Jackson, GS ;
Collinge, J .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 2001, 356 (1406) :185-194
[8]   Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD [J].
Collinge, J ;
Sidle, KCL ;
Meads, J ;
Ironside, J ;
Hill, AF .
NATURE, 1996, 383 (6602) :685-690
[9]   COMPARISON OF MONOCLONAL ANTISERA WITH CONVENTIONAL ANTISERA FOR LEWIS BLOOD-GROUP ANTIGEN DETERMINATION [J].
COWLES, JW ;
COX, MT ;
MCMICAN, A ;
BLUMBERG, N .
VOX SANGUINIS, 1987, 52 (1-2) :83-84
[10]  
CRAWFORD DH, 1988, PROGR TRANSFUSION ME, V3, P175